Cut through the noise, find the signal: Intelligence for serious healthcare leaders
How CMS grades MA plans, what each measure is worth, and where the money moves.
Star Ratings drive approximately $15 billion annually in Quality Bonus Payments. A single half-star change for a large MA organization can mean hundreds of millions in revenue. For example, a plan with 500,000 members moving from 3.5 to 4.0 stars would gain approximately $250-$400 million annually in QBP revenue.
2026 CAHPS/Access weight reduction (4→2)
This is the single largest structural change since QBPs began. Plans that relied on high patient satisfaction to carry their ratings will need to fundamentally restructure quality strategy.
2027 HEI replacing Reward Factor
The incentive shifts from “be consistently good overall” to “reduce disparities for disadvantaged populations.” Plans serving high-SES populations lose the Reward Factor advantage.
Tukey outlier impact
Made 4+ stars significantly harder to achieve. Plans that were borderline 4-star may drop to 3.5, losing QBP eligibility — a potential revenue loss of hundreds of millions for large insurers.
Medication adherence dominance
The three Part D adherence measures (diabetes, hypertension, cholesterol) at weight 3 each have been the single most impactful cluster of measures for a decade. Plans that master adherence consistently achieve high overall ratings.
Looking across two decades, CMS has consistently moved in one direction: away from process measurement and toward outcomes. The 2007 program started with simple operational measures (complaints, access). By 2012, medication adherence became a dominant driver. By 2024, Tukey outliers pushed cut points upward, making high ratings harder. And in 2027, the Health Equity Index signals CMS’s next frontier: not just what outcomes you achieve, but for whom.